Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31614683 | 1.00 | GAA (0.34) | GAAMAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL1393362 | 0.82 | GAA (0.35) | GAAMAPTKMT2A | |
| SCHEMBL29920955 | 0.75 | MAPT (0.37) | GAAMAPTKMT2AALDH1A1 | |
| SCHEMBL29674966 | 0.75 | MAPT (0.43) | GAAMAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL29851037 | 0.75 | GAA (0.36) | GAAMAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL9391171 | 0.75 | MAPT (0.43) | GAAMAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL418340 | 0.75 | MAPT (0.43) | GAAMAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL7643820 | 0.75 | CYP3A4 (0.38) | GAAMAPTKMT2APOLBL3MBTL1 | |
| SCHEMBL1494366 | 0.75 | GAA (0.36) | GAAMAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL4607963 | 0.75 | MAPT (0.37) | GAAMAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186425-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4490147-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| CN-118984823-A | PPARG inverse agonists and uses thereof | 弗拉雷治疗公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20240336594-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2024-10-10 | — | — | US | disclosed |
| EP-4368618-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2024-05-15 | — | — | EP | disclosed |
| CN-117715898-A | Six-membered aryl or heteroaryl amide compound, composition and application thereof | 贝达药业股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023172845-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023279986-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023279986-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| US-5547991-A | NMDA antagonism method | MERRELL PHARMACEUTICALS INC. (US) | 1996-08-20 | — | — | US | disclosed |
| US-5484814-A | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5470870-A | New class of excitatory amino acid antagonist for epilepsy, anxiety or stroke | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0501378-B1 | NMDA Antagonists | MERRELL DOW PHARMA (US) | 1995-01-11 | — | — | EP | disclosed |
| US-5360814-A | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0501378-A1 | NMDA Antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186425-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | GAA 2455/4885MAPT 4588/4885KMT2A 4230/4885 |
| US-20240336594-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | MALT1, CYP51A1, BCR | GAA 75/4885MAPT 1950/4885KMT2A 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.